ConductScience.org, home

Paper19252746

COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.

Wagemakers M and 9 others. Transl Oncol, 2009. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature. Papers, record 19252746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19252746

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
PubMed
Journal
Transl Oncol
PubMed
Year
2009
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
0.92
iCite
Revised in PubMed
2022-03-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wagemakers MMichiel
2van der Wal GEGesiena E
3Cuberes RRosa
4Alvarez IInés
5Andrés EMEva Ma
6Buxens JJordi
7Vela JMJosé M
8Moorlag HHenk
9Mooij JJJan Jakob A
10Molema GGrietje

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115972838Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro.Am J Physiol Cell Physiol2005https://conductscience.org/library/papers/15972838PubMed
210987308Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.Cancer Res2000https://conductscience.org/library/papers/10987308PubMed
315637262Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science2005https://conductscience.org/library/papers/15637262PubMed
42369725Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence.Cancer Res1990https://conductscience.org/library/papers/2369725PubMed
510728691Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.Cancer Res2000https://conductscience.org/library/papers/10728691PubMed
611754039Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs.Biopharm Drug Dispos2001https://conductscience.org/library/papers/11754039PubMed
711606477COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.FASEB J2001https://conductscience.org/library/papers/11606477PubMed
815179620Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.Semin Oncol2004https://conductscience.org/library/papers/15179620PubMed
914751505Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors.Int J Radiat Oncol Biol Phys2004https://conductscience.org/library/papers/14751505PubMed
1014519750Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?J Natl Cancer Inst2003https://conductscience.org/library/papers/14519750PubMed
1111830509Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.Cancer Res2002https://conductscience.org/library/papers/11830509PubMed
1215175435Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004https://conductscience.org/library/papers/15175435PubMed
138551390Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.J Pathol1995https://conductscience.org/library/papers/8551390PubMed
1415607960Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.Cancer Cell2004https://conductscience.org/library/papers/15607960PubMed
1512142044Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.Eur J Cancer2002https://conductscience.org/library/papers/12142044PubMed
1610469752Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.J Natl Cancer Inst1999https://conductscience.org/library/papers/10469752PubMed
1715015658Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089.J Neurooncol2004https://conductscience.org/library/papers/15015658PubMed
1810728694Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.Cancer Res2000https://conductscience.org/library/papers/10728694PubMed
1911389063Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.Cancer Res2001https://conductscience.org/library/papers/11389063PubMed
2010873107Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.Clin Cancer Res2000https://conductscience.org/library/papers/10873107PubMed

See all 28 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
41607422The combination of rosuvastatin and meloxicam enhances the radiotherapy efficacy of MCF7, T-47D, and MDA-MB-231 breast cancer cell lines.Res Pharm Sci2026https://conductscience.org/library/papers/41607422PubMed
39339469Some Aspects and Convergence of Human and Veterinary Drug Repositioning.Molecules2024https://conductscience.org/library/papers/39339469PubMed
38585299
A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs.
Front Vet Sci2024https://conductscience.org/library/papers/38585299PubMed
35734224Effect of Parecoxib Sodium Preemptive Analgesia on the Recovery Period of General Anesthesia in Patients Undergoing Glioma Resection.J Oncol2022https://conductscience.org/library/papers/35734224PubMed
35042267Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays.Drug Res (Stuttg)2022https://conductscience.org/library/papers/35042267PubMed
35038171Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood.J Vet Pharmacol Ther2022https://conductscience.org/library/papers/35038171PubMed
34886785Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways.Drug Metab Lett2021https://conductscience.org/library/papers/34886785PubMed
34854245
Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model.
Vet Med Sci2022https://conductscience.org/library/papers/34854245PubMed
34160092Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration.J Vet Pharmacol Ther2021https://conductscience.org/library/papers/34160092PubMed
34082759Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months.BMC Vet Res2021https://conductscience.org/library/papers/34082759PubMed
33806933Contemporary Mouse Models in Glioma Research.Cells2021https://conductscience.org/library/papers/33806933PubMed
30715649Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.Mol Neurobiol2019https://conductscience.org/library/papers/30715649PubMed
30584371Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo.Cancer Manag Res2018https://conductscience.org/library/papers/30584371PubMed
29254264Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis.Oncotarget2017https://conductscience.org/library/papers/29254264PubMed
27104573Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.Antioxidants (Basel)2016https://conductscience.org/library/papers/27104573PubMed
26871579Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma.PLoS One2016https://conductscience.org/library/papers/26871579PubMed
24416158Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.PLoS One2014https://conductscience.org/library/papers/24416158PubMed
24281089Role of inflammation and oxidative stress mediators in gliomas.Cancers (Basel)2010https://conductscience.org/library/papers/24281089PubMed
23280445
Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.
J Neurosci Res2013https://conductscience.org/library/papers/23280445PubMed
22678114Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.Carcinogenesis2012https://conductscience.org/library/papers/22678114PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19252746

GET https://conductscience.org/api/papers/v1/19252746/references?page=2